Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables: 2009-2025

Historic Receivables for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $252.6 million.

  • Ani Pharmaceuticals' Receivables rose 28.65% to $252.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $920.3 million, marking a year-over-year increase of 32.05%. This contributed to the annual value of $221.7 million for FY2024, which is 36.80% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Receivables of $252.6 million as of Q3 2025, which was up 11.95% from $225.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Receivables' 5-year high stood at $252.6 million during Q3 2025, with a 5-year trough of $91.9 million in Q1 2021.
  • For the 3-year period, Ani Pharmaceuticals' Receivables averaged around $194.9 million, with its median value being $178.8 million (2023).
  • Its Receivables has fluctuated over the past 5 years, first surged by 62.35% in 2022, then fell by 4.90% in 2023.
  • Ani Pharmaceuticals' Receivables (Quarterly) stood at $128.5 million in 2021, then spiked by 32.61% to $170.4 million in 2022, then dropped by 4.90% to $162.1 million in 2023, then spiked by 36.80% to $221.7 million in 2024, then climbed by 28.65% to $252.6 million in 2025.
  • Its Receivables stands at $252.6 million for Q3 2025, versus $225.7 million for Q2 2025 and $220.3 million for Q1 2025.